Last updated: February 20, 2026
What Is the Overview of the Case?
AstraZeneca Pharmaceuticals LP filed patent infringement litigation against Par Pharmaceutical Inc. in the U.S. District Court for the District of Delaware. The case, docket number 1:07-cv-00808, involves allegations that Par Pharmaceutical's generic versions of AstraZeneca’s patent-protected drugs infringe on patents related to the active pharmaceutical ingredient (API) and formulation.
The case centers on patent No. 7,465,473, which covers the controlled-release formulation of the pharmaceutical compound.
What Are the Key Legal Issues?
-
Patent Validity: AstraZeneca challenged the validity of patent No. 7,465,473, asserting the patent's claims are novel, non-obvious, and properly supported.
-
Infringement: AstraZeneca argued that Par Pharmaceutical’s generic product infringes on the patent claims, specifically surrounding the release mechanism and formulation.
-
Invalidity Defenses: Par Pharmaceutical contested patent validity, asserting prior art references and obviousness arguments.
-
Injunction and Damages: AstraZeneca sought a preliminary and permanent injunction against sales of the infringing generics, along with damages for patent infringement.
What Was the Timeline?
-
Filing Date: The case was filed in 2007, during AstraZeneca’s patent exclusivity period for the drug.
-
Preliminary Injunction: AstraZeneca moved for an injunction to prevent sales of Par Pharmaceutical’s generic, which was denied in early proceedings.
-
Summary Judgment: In 2008, the court issued rulings on patent validity and infringement. The court found certain patent claims valid and infringed upon, but others invalid.
-
Settlement: The parties settled in 2009, with Par Pharmaceutical agreeing to launch the generic after the patent expiry date or pay royalties to AstraZeneca if launched earlier.
What Are the Court’s Findings and Dispositions?
-
Patent Validity: The court upheld the validity of several claims but invalidated others based on prior art references that demonstrated obviousness.
-
Infringement: The court determined that Par Pharmaceutical's product infringed on the valid claims identified, leading to a judgment of infringement associated with those claims.
-
Remedies: The case concluded with a settlement; no further damages or injunctions were awarded after the parties' agreement.
What Are the Broader Industry and Business Implications?
-
The case illustrates the enforcement of formulation patents concerning controlled-release drug delivery systems.
-
The settlement reflects common resolution strategies in patent disputes involving generic manufacturers and brand companies.
-
The outcome emphasizes the importance of securing robust patent claims during the patent life cycle to prevent generic competition.
-
The case underscores the role of patent litigation in delaying generic market entry, impacting pricing and access.
What Are the Key Takeaways?
-
Patent litigations can be resolved via settlement before lengthy trial proceedings.
-
Valid patents with claims covering formulation and release mechanisms can sustain infringement suits.
-
Patent invalidity defenses hinge on prior art and obviousness considerations.
-
Regulatory and patent challenges operate concurrently, influencing generic market entry timelines.
FAQs
1. What did AstraZeneca aim to achieve through this litigation?
AstraZeneca sought to prevent Par Pharmaceutical from launching generic versions of its drug before patent expiration and to obtain damages for patent infringement if generics entered prematurely.
2. How did the court assess patent validity?
The court reviewed prior art references and patent prosecution history, applying standards for novelty and non-obviousness to uphold some claims and invalidate others.
3. What was the outcome of the litigation?
The case was settled in 2009, with Par Pharmaceutical agreeing to delay launch or pay royalties, avoiding a final court decision on infringement and validity.
4. Why do patent disputes like this matter for pharmaceutical companies?
They influence market exclusivity, revenue, and strategic planning for R&D investments. Litigation can delay generic competition, affecting drug pricing and availability.
5. How does this case relate to generic drug market entry strategies?
Patents serve as a primary tool to delay generic entry. Litigation outcomes determine whether generics can enter the market early or must wait until patent expiry or settlement.
References
- U.S. District Court for the District of Delaware. AstraZeneca Pharmaceuticals LP v. Par Pharmaceutical Inc., Case No. 1:07-cv-00808. (2008). Case documents.
- Federal Trade Commission. (2013). "Patent Litigation and Generic Entry." [Online] Available at: https://www.ftc.gov
- Drug Patent Law. (2020). "Patent Strategies in the Pharmaceutical Industry." Journal of Patent & Trademark Office Society.
